08:57 AM EDT, 05/07/2026 (MT Newswires) -- Ligand Pharmaceuticals (LGND) reported Q1 adjusted earnings of $1.63 per diluted share, up from $1.33 a year earlier.

Revenue for the quarter ended March 31 was $51.7 million, up from $45.3 million a year earlier.

Analysts surveyed by FactSet expected $58.7 million.

The company said it expects full-year 2026 adjusted earnings of approximately $8.50 to $9.50 per diluted share.

Analysts surveyed by FactSet expect $8.99.

The company expects full-year 2026 revenue of $270 million to $310 million.

Analysts polled by FactSet expect $281.9 million.

Ämnen i artikeln

Ligand Pharmaceuticals

Senast

212,27

1 dag %

−8,72%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån